CC 90002

Drug Profile

CC 90002

Alternative Names: Anti-CD47 Antibody - Celgene; Ca ImmRx; CC-90002; INBRX-103

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Inhibrx
  • Developer Celgene Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes

Most Recent Events

  • 01 Feb 2016 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) (NCT02641002)
  • 01 Feb 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02641002)
  • 07 Jan 2016 Celgene corporation plans a phase I trial for Acute myeloid leukaemia in USA (NCT02641002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top